Claim · model-written summary
Compound 1 inhibited triglycerides in oleic acid-induced HepG2 cells better than atorvastatin.
- Treatment
- 1e0
- Outcome
- triglyceride (TG) inhibitory effecte0
- Direction
- bettere0
- Comparator
- atorvastatine0
- Setting
- oleic acid-induced HepG2 cellse0
Not reportedTaxonMaterialGeneCompoundOrgan / stageInteractorInteractor roleSecond interactorSecond interactor roleValueQualifier
Verbatim
e0“Four compounds ( 1, 2, 4, and 5 ) exhibited a better triglyceride (TG) inhibitory effect than atorvastatin in oleic acid-induced HepG2 cells”
Title
Zhuohan Hu; Lei Huang; Lang Wang; et al. Organic Letters 2026. doi:10.1021/acs.orglett.6c00023
Other claims from this paper (9)
- Observation Hyperacmoses A–C and two precursor compounds were purified from Hypericum acmosepalum.
- Observation Compounds 1 and 2 have the first reported seco-norPPAP 5/6/5/6/5 pentacyclic framework.
- Observation Compound 3 has the first reported seco-norPPAP 5/5/6/6 tetracyclic core.
- Observation Three rare PPAPs shared a biosynthetic precursor.
- Mechanism The authors propose that oxidation at different precursor positions could yield different PPAP types.
- Intervention effect Compound 2 inhibited triglycerides in oleic acid-induced HepG2 cells better than atorvastatin.
- Intervention effect Compound 4 inhibited triglycerides in oleic acid-induced HepG2 cells better than atorvastatin.
- Intervention effect Compound 5 inhibited triglycerides in oleic acid-induced HepG2 cells better than atorvastatin.
- Mechanism Compound 1 suppressed FASN and ACACA protein expression by targeting ACSS2.